Read by QxMD icon Read

Chemotherapy induced cardiotoxicity

Marijke Linschoten, Arco J Teske, Maarten J Cramer, Elsken van der Wall, Folkert W Asselbergs
Chemotherapy-related cardiac dysfunction is a significant side effect of anticancer treatment. Risk stratification is based on clinical- and treatment-related risk factors that do not adequately explain individual susceptibility. The addition of genetic variants may improve risk assessment. We conducted a systematic literature search in PubMed and Embase, to identify studies investigating genetic risk factors for chemotherapy-related cardiac dysfunction. Included were articles describing genetic variants in humans altering susceptibility to chemotherapy-related cardiac dysfunction...
January 2018: Circ Genom Precis Med
Jing Wu, Chao Sun, Ruoyi Wang, Juan Li, Meng Zhou, Mi Yan, Xia Xue, Chuanxin Wang
Cardiotoxicity is a dose-dependent side effect of epirubicin that restricts its clinical utility in cancer chemotherapy. Paeonol is an active constituent with various biological activities, including the protection of antineoplastic-induced toxicities. In the present study, we investigated the protective effect of paeonol on epirubicin-induced cardiotoxicity and explored the underlying mechanism. A series of methods were used including a MTT assay, flow cytometry, echocardiography, TUNEL staining, a dual-luciferase reporter assay, immunofluorescence, RT-PCR and Western blotting...
March 2, 2018: Chemico-biological Interactions
Subhadip Hajra, Arup Ranjan Patra, Abhishek Basu, Sudin Bhattacharya
Doxorubicin (DOX) is an anthracycline group of antibiotic available for the treatment of broad spectrum of human cancers. However, patient receiving DOX-therapy, myelosuppression and genotoxicity which may lead to secondary malignancy and dose dependent cardiotoxicity is an imperative adverse effect. Mechanisms behind the DOX-induced toxicities are increased level of oxidative damage, inflammation and apoptosis. Therefore, in search of a potential chemoprotectant, naturally occurring glucosinolate breakdown product Indole-3-Carbinol (I3C) was evaluated against DOX-induced toxicities in Swiss albino mice...
February 26, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
Himangshu Sonowal, Pabitra Pal, Kirtikar Shukla, Ashish Saxena, Satish K Srivastava, Kota V Ramana
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy...
February 16, 2018: Biochemical Pharmacology
Shuxu Du, Yaqian Huang, Hongfang Jin, Tianyou Wang
Over the past few decades, the number of long term survivors of childhood cancers has been increased exponentially. However, among these survivors, treatment-related toxicity, especially cardiotoxicity, is becoming the essential cause of morbidity and mortality. Thus, preventing the treatment-related adverse effects is important to increase the event free survival during the treatment of cancer in children and adolescents. Accumulating evidence has demonstrated that hydrogen sulfide (H2 S) exerts a protective role on cardiomyocytes through a variety of mechanisms...
2018: Frontiers in Pharmacology
Danúbia Silva Dos Santos, Guilherme Visconde Brasil, Isalira Peroba Rezende Ramos, Fernanda Cristina Paccola Mesquita, Tais Hanae Kasai-Brunswick, Michelle Lopes Araújo Christie, Gustavo Monnerat Cahli, Raiana Andrade Quintanilha Barbosa, Sandro Torrentes da Cunha, Jonathas Xavier Pereira, Emiliano Medei, Antonio Carlos Campos de Carvalho, Adriana Bastos Carvalho, Regina Coeli Dos Santos Goldenberg
BACKGROUND: Doxorubicin (Dox) is a chemotherapy drug with limited application due to cardiotoxicity that may progress to heart failure. This study aims to evaluate the role of cardiomyocytes derived from mouse embryonic stem cells (CM-mESCs) in the treatment of Dox-induced cardiomyopathy (DIC) in mice. METHODS: The mouse embryonic stem cell (mESC) line E14TG2A was characterized by karyotype analysis, gene expression using RT-PCR and immunofluorescence. Cells were transduced with luciferase 2 and submitted to cardiac differentiation...
February 5, 2018: Stem Cell Research & Therapy
H William Strauss, Giuliano Mariani
No abstract text is available yet for this article.
February 1, 2018: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
Fabricio Bragança Silva, Walckiria Garcia Romero, Ana Ligia Rodrigues de Abreu Carvalho, Gleyce Ariadne Alves Souza, Erick Roberto Gonçalves Claudio, Glaucia Rodrigues Abreu
There has been an increase in deaths from cardiovascular diseases following breast cancer therapy. Evidence has shown that this outcome is, in part, associated with cardiotoxicity induced by the chemotherapeutic drugs and the increase in oxidative stress. The aim of this study was to evaluate the effects of chemotherapy and hormone therapy with tamoxifen on the biomarkers of cardiac injury and oxidative stress in women with breast cancer.Thirty women were followed-up for 1 year and were divided into 3 groups according to the treatment protocol: women treated only with tamoxifen and clinical follow up for 12 months (Tam, n = 10); women treated only with chemotherapy for 6 months with clinical follow up for an additional 6-month period (Chemo, n = 10); and women who received chemotherapy for 6 months followed by a 6-month period only with tamoxifen therapy and clinical follow up (Chemo + Tam, n = 10)...
November 2017: Medicine (Baltimore)
Jonathan P Stack, Javid Moslehi, Nazish Sayed, Joseph C Wu
Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies...
January 25, 2018: European Heart Journal
Hiroshi Akazawa
Recent progress in cancer chemotherapy has improved the long-term outcome for cancer patients. Under such circumstances, it is increasingly of clinical importance to manage the cardiovascular complications, which are related to both cancer itself and adverse effects of cancer therapies. Among the most concerning as cardiovascular complications of cancer therapies is chemotherapy-induced cardiotoxicity or chemotherapy-related cardiac dysfunction(CTRCD). CTRCD has been intuitively classified according to the extent of structural abnormalities and degree of reversibility; type 1 is irreversible and dose-dependent with structural abnormalities, and type 2 is reversible after cessation of treatment and dose-independent without structural abnormalities...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Seok Soon Park, Dong Min Lee, Jun Hee Lim, Dongjoo Lee, Sang Jun Park, Hwan Myung Kim, Seonghyang Sohn, Gyesoon Yoon, Young Woo Eom, Seong-Yun Jeong, Eun Kyung Choi, Kyeong Sook Choi
Elevated Bcl-xL expression in cancer cells contributes to DOX resistance, leading to failure in chemotherapy. In addition, the clinical use of high-dose doxorubicin (DOX) in cancer therapy has been limited by issues with cardiotoxicity and hepatotoxicity. Here, we show that co-treatment with pyrrolidine dithiocarbamate (PDTC) attenuates DOX-induced apoptosis in Chang-L liver cells and human hepatocytes, but overcomes DOX resistance in Bcl-xL-overexpressing Chang-L cells and several hepatocellular carcinoma (HCC) cell lines with high Bcl-xL expression...
January 10, 2018: Carcinogenesis
Fulya Benzer, Fatih Mehmet Kandemir, Mustafa Ozkaraca, Sefa Kucukler, Cuneyt Caglayan
Doxorubicin (DXR) is a highly effective drug for chemotherapy. However, cardiotoxicity reduces its clinical utility in humans. The present study aimed to assess the ameliorative effect of curcumin against DXR-induced cardiotoxicity in rats. Rats were subjected to oral treatment of curcumin (100 and 200 mg/kg body weight) for 7 days. Cardiotoxicity was induced by single intraperitoneal injection of DXR (40 mg/kg body weight) on the 5th day and the rats sacrificed on 8th day. Curcumin ameliorated DXR-induced lipid peroxidation, glutathione depletion, decrease in antioxidant (superoxide dismutase, catalase, and glutathione peroxidase) enzyme activities, and cardiac toxicity markers (CK-MB, LDH, and cTn-I)...
January 5, 2018: Journal of Biochemical and Molecular Toxicology
I Skrypnyk, G Maslova, T Lymanets, I Gusachenko
AIM: To evaluate the effectiveness of L-arginine in the prevention of endothelial dysfunction, which may be a predictor of anthracycline-induced myocardial injury, in patients with acute leukemia (AL) on the background of anthracycline antibiotics low cumulative doses from 100 to 200 mg/m2. MATERIALS AND METHODS: A total of 81 adult AL patients (38 males and 43 females with the age of 16-59 years) were studied. The patients were divided into two groups: group I (n = 34), AL patients treated with chemotherapy (CT) and L-arginine hydrochloride; group II (n = 47) - AL patients treated with CT only...
December 2017: Experimental Oncology
Katarzyna Mizia-Stec, Marek Elżbieciak, Maciej T Wybraniec, Monika Różewicz, Artur Bodys, Wojciech Braksator, Zbigniew Gąsior, Piotr Gościniak, Tomasz Hryniewiecki, Jarosław Kasprzak, Andrzej Wojtarowicz, Barbara Zdziarska, Edyta Płońska-Gościniak
The cardiotoxicity of chemotherapy (CTx) for non-Hodgkin's lymphomas is not well recognized. In order to facilitate individual risk counseling for patients, we analyzed the effect of CTx on echocardiographic indices in regard to clinical data in patients treated for non-Hodgkin's lymphoma (NHL). A prospective multicenter ONCO-ECHO trial included 67 patients with NHL (45 patients with DLBCL (diffuse large B cell lymphoma) and 22 with non-DLBCL). Patients received standard CTx, primarily R-CHOP, CHOP, R-COP and COP regimens...
December 22, 2017: Medical Oncology
Xiaoyan Liu, Yanlin Zhu, Xue Lin, Ligang Fang, Xiaowei Yan
RATIONALE: Anthracyclines cardiotoxicity characterized by dilated myocardiopathy has been well described in the literature. However, anthracyclines-induced valvular diseases have been seldom reported. PATIENT CONCERNS: In this study, we present the case of a 62-year-old Chinese female patient with breast cancer developing severe mitral regurgitation after anthracycline exposure. DIAGNOSES: The patient was diagnosed with mitral regurgitation with preserved left ventricular ejection fraction and normal cardiac chamber dimensions in the sixth month after the last course of anthracycline-containing chemotherapy...
December 2017: Medicine (Baltimore)
Robert W Loar, Cory V Noel, Hari Tunuguntla, John L Colquitt, Ricardo H Pignatelli
Chemotherapy-induced cardiotoxicity in adults and children is a topic with a growing interest in the cardiology literature. The ability to detect cardiac dysfunction in a timely manner is essential in order to begin adequate treatment and prevent further deterioration. This article aims to provide a review on the myocardial injury process, chemotherapeutic agents that lead to cardiotoxicity, the definition of cardiotoxicity, and the methods of timely detection and treatment.
January 2018: Congenital Heart Disease
Li-Rong Yu, Zhijun Cao, Issam Makhoul, Jaclyn R Daniels, Suzanne Klimberg, Jeanne Y Wei, Jane Pf Bai, Jinong Li, Julia T Lathrop, Richard D Beger, Valentina K Todorova
Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with >10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5-10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment)...
February 2018: Experimental Biology and Medicine
Diane Krasnopero, Alfred Asante-Korang, Jeffrey Jacobs, Stacie Stapleton, Jennifer Carapellucci, Mathew Dotson, Gary Stapleton
Ventricular assist devices are used in children with heart failure as a bridge to myocardial recovery or cardiac transplantation. Anthracyclines cause cardiac toxicity and may result in acute or long-term cardiac failure. We describe the use of a ventricular assist device as a bridge to recovery in a child with severe acute anthracycline-induced cardiomyopathy, and we review the associated literature. A 6-year-old girl was treated for acute myeloblastic leukaemia with daunorubicin and mitoxantrone. After 2 weeks her final dose of chemotherapy, her Left Ventricular Ejection Fraction decreased to 21%...
March 2018: Cardiology in the Young
Elena Gazzano, Barbara Rolando, Konstantin Chegaev, Iris C Salaroglio, Joanna Kopecka, Isabella Pedrini, Simona Saponara, Matteo Sorge, Ilaria Buondonno, Barbara Stella, Alessandro Marengo, Massimo Valoti, Mara Brancaccio, Roberta Fruttero, Alberto Gasco, Silvia Arpicco, Chiara Riganti
Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide (NO)-releasing group overcomes resistance by inducing a NO-mediated inhibition of Pgp. Here we produced the first liposomal formulations of this nitrooxy-doxorubicin decorated with folic acid (FA), termed LNDF, in order to improve their active targeting against Pgp-expressing tumors. Folate was inserted onto liposomes surface using two different methods and the formulations were compared with respect to their technological features and in vitro behavior...
January 28, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
Hanna Aula, Tanja Skyttä, Suvi Tuohinen, Tiina Luukkaala, Mari Hämäläinen, Vesa Virtanen, Pekka Raatikainen, Eeva Moilanen, Pirkko-Liisa Kellokumpu-Lehtinen
AIM: To identify patients with breast cancer at risk for cardiotoxicity, we evaluated homoarginine (HA) behavior during adjuvant treatment. PATIENTS AND METHODS: Eighty-one patients received radiotherapy (RT) with or without endocrine treatment, and 19 received chemotherapy, RT and endocrine therapy. Serum HA, asymmetric dimethylarginine (ADMA) and high-sensitivity cardiac troponin T (hscTnT) were measured and echocardiography was performed before chemotherapy, and before and after RT...
December 2017: Anticancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"